Piet Wigerinck, PhD

Chairman of the Scientific Advisory Board

Piet Wigerinck, PhD, is the former CSO of Galapagos. Under his leadership, Galapagos has developed a large pipeline of novel mechanism of action drugs for auto-immune diseases; Jyseleca was approved for rheumatoid arthritis in 2020 in the EU and Japan. He has supervised multiple successful proofs-of-concept patient studies, including filgotinib and ziritaxestat. Prior to his tenure at Galapagos, he was Vice President, Drug Discovery, Early Development and CM&C at Tibotec-Virco Comm. VA (a subsidiary of Johnson & Johnson). Under his leadership at Tibotec, Prezista™, Olysio™, and Rekambys™ were selected, moved forward into clinical trials and were later approved. Piet Wigerinck has over 30 years of R&D experience in the pharmaceutical industry and biotechnology. He is an independent board member of various Biotech and Pharma including the French pharma company Ipsen SA.

Management team

Scientific Advisor

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

Scientific Advisory Board

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow

Legal notices

Ermium Therapeutics registered under number SIRET 85199803900016, is a simplified stock company.

Located at 16 Boulevard Saint Germain 75005 PARIS and with a registered capital of €1,352, it specializes in research and development in biotechnology (7211Z).

Intellectual property :

This site constitutes a work protected by copyright in force in France. In addition, unless otherwise stated, the intellectual property rights in the documents contained in the site (texts, photographs, images, etc.) and each of the elements created for this site are the exclusive property of Ermium Therapeutics. Reproduction of all elements published on the site Ermium.com is expressly prohibited (article 122.4 of the code of the intellectual property).

Sites linked directly or indirectly to the Ermium.com site are not under its control. Consequently, Ermium Therapeutics assumes no responsibility for the information published on these sites.

Hosting

OVH:
SAS with capital of €10,069,020
RCS Lille Métropole 424,761,419,00045
APE Code 2620Z
VAT number: FR 22 424 761 419
Headquarters: 2 rue Kellermann – 59100 Roubaix – France

Publication Director :
Joel Crouzet

contact@ermium.com

Stages de couture

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Ateliers du dimanche

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Cours enfant

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours réalisation 

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours coupe

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Préparation au C.A.P.

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.